Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report

Eriko Fujimoto; Takashi Yokoi; Koji Mikami; Shingo Kanemura; Eisuke Shibata; Daisuke Horio; Yuichi Koda; Yoshiki Negi; Yumiko Akano; Akio Tada; Toshiyuki Minami; Kozo Kuribayashi; Takashi Kijima

doi:10.1159/000489392

Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report

Case Rep Oncol. 2018 May 31;11(2):336-340. doi: 10.1159/000489392. eCollection 2018 May-Aug.

Authors

Eriko Fujimoto¹, Takashi Yokoi^{1

2}, Koji Mikami^{1

2}, Shingo Kanemura^{1

2}, Eisuke Shibata^{1

2}, Daisuke Horio¹, Yuichi Koda¹, Yoshiki Negi^{1

2}, Yumiko Akano¹, Akio Tada¹, Toshiyuki Minami^{1

2}, Kozo Kuribayashi^{1

2}, Takashi Kijima^{1

2}

Affiliations

¹ Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
² Department of Thoracic Oncology, Hyogo College of Medicine, Hyogo, Japan.

Abstract

Pulmonary pleomorphic carcinoma (PPC) has a poor prognosis due to the poor results of treatment with systemic chemotherapy. We report the case of a 73-year-old woman with PPC who showed a favorable response to nivolumab. As first-line treatment for postoperative recurrence, she received carboplatin and nanoparticle albumin-bound paclitaxel. However, 12 months later, a new metastatic lymph node appeared. Nivolumab was administered as second-line treatment, and the patient showed a favorable prolonged response. The effects of treatment of PPC with nivolumab seem promising. The results of a future prospective study are expected to identify indicators for the treatment of PPC.

Keywords: Nivolumab; Programmed cell death ligand-1; Pulmonary pleomorphic carcinoma.

Publication types

Case Reports